Skip to content
How It Works
Explore
Ask a Question Resources Pricing
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 25 peer-reviewed journal articles Updated
Cardiology

Managing Your Heart: Rate vs. Rhythm Control

At a Glance

For atrial fibrillation, rate control slows a fast heartbeat without necessarily restoring the heart's regular rhythm, while rhythm control aims to restore and maintain it. Doctors may use either or both, considering symptoms, AFib duration, heart function, medication risks, and stroke prevention.

When managing Atrial Fibrillation, your care team will focus on two main goals: preventing stroke and managing your heart’s activity. To manage your heart’s activity, there are two primary pathways—rate control and rhythm control. These strategies are not “either-or” choices; they are complementary tools that your doctor may use together to help you feel your best.

Strategy 1: Rate Control (The “Speed Limit”)

The goal of rate control is not to stop the AFib, but to keep your heart from beating too fast [1]. Think of it as setting a “speed limit” for your heart. This protects the heart muscle from weakening over time and helps reduce symptoms like palpitations.

  • Target: A common starting goal is a resting heart rate below 110 beats per minute [2]. If you still feel symptoms at this rate, your doctor may aim for a stricter target, such as below 80–90 beats per minute [3].
  • Common Medications:
    • Beta-blockers: Often the first choice, these slow the electrical signals passing through the heart [4].
    • Calcium Channel Blockers: Medications like diltiazem or verapamil are effective but are typically avoided if you have certain types of heart failure (reduced ejection fraction) [5][6].
    • Digoxin: This may be used as an add-on therapy, especially for older patients or those with heart failure, but it requires careful monitoring of your kidney function and blood levels [7][8].

Strategy 2: Rhythm Control (The “Normal Beat”)

Rhythm control aims to restore and maintain your heart’s natural rhythm, known as sinus rhythm [9]. This strategy is often prioritized if you are highly symptomatic or have been recently diagnosed.

  • Common Medications (Antiarrhythmics): These drugs require specialist supervision.
    • Flecainide or Propafenone: Used for patients with “electrically” healthy hearts—meaning no history of heart attack, significant structural disease, or significant scarring, and usually combined with an AV-nodal-blocking strategy [10].
    • Amiodarone: Highly effective and can be used in selected patients with reduced ejection fraction, but it carries risks of pulmonary, thyroid, hepatic, and ocular toxicity, requiring regular screening [11][12].
    • Sotalol and Dronedarone: Sotalol requires specific monitoring of your kidney function and the heart’s electrical “reset” time (the QT interval). Dronedarone has important contraindications, notably for patients with symptomatic heart failure or permanent AFib [13][14].

The Power of “Early” Rhythm Control

In recent years, medical guidelines have shifted to favor starting rhythm control sooner rather than later [15]. A landmark study called EAST-AFNET 4 found that for selected patients diagnosed within the prior year and with cardiovascular conditions, a systematic “early rhythm control” strategy—predominantly antiarrhythmic-drug based, with ablation used in a minority—reduced a composite of cardiovascular death, stroke, and heart failure hospitalizations [16][17]. The study supports considering early rhythm control and suggests it may help prevent the “remodeling” (scarring) that makes AFib harder to treat later [18].

Resetting the Rhythm: Cardioversion

Cardioversion is a procedure used to “reset” the heart from AFib back into a normal rhythm. It can be done in two ways:

  1. Electrical Cardioversion: A controlled electrical shock is delivered to the heart while you are under brief sedation [19]. It is highly effective at stopping an active episode of AFib [20].
  2. Pharmacological Cardioversion: Using specialized intravenous or oral medications to nudge the heart back into rhythm [19].

Crucial Safety Note on Anticoagulation: If your AFib has lasted for at least 48 hours, or is of unknown duration, you must generally be on therapeutic blood thinners for at least three weeks before a cardioversion, or have a special ultrasound (TEE) to ensure no clots are present in the heart [21][22]. Even more importantly, you must continue anticoagulation for at least four weeks AFTER the cardioversion (and longer when your stroke risk warrants it). Never start or stop anticoagulation around cardioversion without your clinician’s explicit instruction.

Choosing Your Path

While your doctor will guide the decision, the following are factors that may prompt discussion of one strategy over the other:

Factors that may favor Rhythm Control Factors that may favor Rate Control
New Diagnosis (<1 year) or recent onset [16] Older Age or minimal symptoms [2]
Highly Symptomatic (to improve quality of life) [23] Asymptomatic (if the patient feels well) [2]
Heart Failure (often preferred to protect heart function depending on subtype) [24] Long-standing AFib (if the heart has too much structural scarring) [20]

Ultimately, the goal is “shared decision-making.” You and your doctor will weigh the benefits of a normal rhythm against the potential side effects of medications or procedures [25].

Medication Safety Box

Important rules for rate and rhythm medications:

  • Do not stop abruptly: Suddenly stopping beta-blockers, antiarrhythmics, or anticoagulants can cause a dangerous rebound in heart rate, rhythm, or clotting risk.
  • Watch for adverse effects: Report severe extreme fatigue, low blood pressure, a very slow pulse, worsening breathlessness, or fainting to your doctor immediately.
  • Drug interactions: Always check with your pharmacist before starting new supplements or over-the-counter meds, as antiarrhythmics have many critical interactions.

Common questions in this guide

What is the difference between rate control and rhythm control for AFib?
Rate control slows the heart so it does not beat too quickly, but AFib may continue. Rhythm control aims to restore and maintain the heart’s normal rhythm. Your clinician may use one approach or both, depending on your symptoms and heart health.
Which AFib treatment strategy is right for me?
The choice depends on your symptoms, how long AFib has been present, age, heart function, other cardiovascular conditions, and preferences. Rhythm control may be considered sooner for people with a recent diagnosis or significant symptoms, while rate control may be reasonable for people with few symptoms or long-standing AFib. Your cardiology team can individualize the plan.
What heart rate should I aim for with AFib rate control?
A common initial goal is a resting heart rate below 110 beats per minute. If symptoms continue, your doctor may set a stricter goal, such as below 80 to 90 beats per minute. Your target should be tailored to your health and set with your clinician.
Do I need blood thinners for AFib cardioversion?
If AFib has lasted 48 hours or more, or its duration is unknown, people generally need therapeutic blood thinners for at least three weeks before cardioversion, unless a special ultrasound shows that no clot is present. Blood thinners usually continue for at least four weeks afterward and longer when stroke risk warrants it. Never start or stop anticoagulation without explicit instructions from your clinician.
Can early rhythm control help after a new AFib diagnosis?
In selected people diagnosed within the previous year who also have cardiovascular conditions, the EAST-AFNET 4 study found that a systematic early rhythm-control strategy reduced the combined risk of cardiovascular death, stroke, and heart-failure hospitalizations. Whether this approach fits you depends on your health, AFib pattern, treatment risks, and preferences.
What monitoring is needed for AFib rhythm-control medicines?
Monitoring depends on the medicine. Amiodarone may require lung, thyroid, liver, and eye checks, while sotalol requires kidney-function monitoring and an electrocardiogram measurement called the QT interval. Do not stop these medicines abruptly, and promptly report fainting, severe fatigue, a very slow pulse, low blood pressure, or worsening breathlessness.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Am I a better candidate for a rate-control or a rhythm-control strategy given my current symptoms and how long I have had AFib?
  2. 2.How does the health of my heart muscle—such as my ejection fraction or any coronary disease—limit which rhythm-control medications I can safely take?
  3. 3.Since my diagnosis is relatively recent, does the EAST-AFNET 4 study's focus on 'early rhythm control' apply to me?
  4. 4.If we choose a rate-control strategy, what is our target heart rate, and how will we know if it's working well enough?
  5. 5.What are the long-term monitoring requirements for the specific medications you are recommending (such as thyroid or lung tests)?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (25)
  1. 1

    Comparison of non-dihydropyridine calcium channel blockers with beta blockers as treatment for atrial fibrillation: protocol for a systematic review with meta-analysis.

    Koldenhof T, Gareb B, Smit MD, et al.

    Systematic reviews 2026; (15(1)):44 doi:10.1186/s13643-025-03035-3.

    PMID: 41501960
  2. 2

    Rate control versus rhythm control in atrial fibrillation: lessons learned from clinical trials of atrial fibrillation.

    Waldo AL

    Progress in cardiovascular diseases 2015; (58(2)):168-76.

    PMID: 26260611
  3. 3

    Emergency medicine considerations in atrial fibrillation.

    Long B, Robertson J, Koyfman A, et al.

    The American journal of emergency medicine 2018; (36(6)):1070-1078 doi:10.1016/j.ajem.2018.01.066.

    PMID: 29395765
  4. 4

    2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.

    Joglar JA, Chung MK, Armbruster AL, et al.

    Circulation 2024; (149(1)):e1-e156 doi:10.1161/CIR.0000000000001193.

    PMID: 38033089
  5. 5

    Safety of Intravenous Diltiazem in Reduced Ejection Fraction Heart Failure with Rapid Atrial Fibrillation.

    Jandali MB

    Clinical drug investigation 2018; (38(6)):503-508 doi:10.1007/s40261-018-0631-7.

    PMID: 29478238
  6. 6

    Acute management of atrial fibrillation in congestive heart failure with reduced ejection fraction in the emergency department.

    Hasbrouck M, Nguyen TT

    The American journal of emergency medicine 2022; (58()):39-42 doi:10.1016/j.ajem.2022.03.058.

    PMID: 35623182
  7. 7

    Rate control in atrial fibrillation.

    Van Gelder IC, Rienstra M, Crijns HJ, Olshansky B

    Lancet (London, England) 2016; (388(10046)):818-28.

    PMID: 27560277
  8. 8

    Prognostic impact of digoxin use for rate control of atrial fibrillation in patients ≥75 years of age.

    La Rovere MT, Traversi E

    Monaldi archives for chest disease = Archivio Monaldi per le malattie del torace 2018; (88(2)):954 doi:10.4081/monaldi.2018.954.

    PMID: 29877663
  9. 9

    Rhythm control in atrial fibrillation.

    Piccini JP, Fauchier L

    Lancet (London, England) 2016; (388(10046)):829-40.

    PMID: 27560278
  10. 10

    When Rhythm Control Backfires: Flecainide-Precipitated Transient Cardiomyopathy in the Setting of Electrical Cardioversion.

    Pagan Morales K, Shah D, Feldman D

    Cureus 2026; (18(5)):e108713 doi:10.7759/cureus.108713.

    PMID: 42291924
  11. 11

    The role of amiodarone in contemporary management of complex cardiac arrhythmias.

    Mujović N, Dobrev D, Marinković M, et al.

    Pharmacological research 2020; (151()):104521 doi:10.1016/j.phrs.2019.104521.

    PMID: 31756386
  12. 12

    Amiodarone Therapy: Updated Practical Insights.

    Șorodoc V, Indrei L, Dobroghii C, et al.

    Journal of clinical medicine 2024; (13(20)) doi:10.3390/jcm13206094.

    PMID: 39458044
  13. 13

    Dronedarone Versus Sotalol in Antiarrhythmic Drug-Naive Veterans With Atrial Fibrillation.

    Pundi K, Fan J, Kabadi S, et al.

    Circulation. Arrhythmia and electrophysiology 2023; (16(8)):456-467 doi:10.1161/CIRCEP.123.011893.

    PMID: 37485722
  14. 14

    Dronedarone: Basic Pharmacology and Clinical Use.

    Tadros R, Nattel S, Andrade JG

    Cardiac electrophysiology clinics 2016; (8(2)):453-65.

    PMID: 27261834
  15. 15

    New recommendations for rhythm control-What has changed in the 2023 ACC/AHA/ACCP/HRS and 2024 ESC guidelines for atrial fibrillation, and where does dronedarone fit in?

    Naccarelli GV, Rackley J, Boriani G

    American heart journal plus : cardiology research and practice 2025; (60()):100645 doi:10.1016/j.ahjo.2025.100645.

    PMID: 41552718
  16. 16

    Early Rhythm-Control Therapy in Patients with Atrial Fibrillation.

    Kirchhof P, Camm AJ, Goette A, et al.

    The New England journal of medicine 2020; (383(14)):1305-1316 doi:10.1056/NEJMoa2019422.

    PMID: 32865375
  17. 17

    Anticoagulation, therapy of concomitant conditions, and early rhythm control therapy: a detailed analysis of treatment patterns in the EAST - AFNET 4 trial.

    Metzner A, Suling A, Brandes A, et al.

    Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology 2022; (24(4)):552-564 doi:10.1093/europace/euab200.

    PMID: 34473249
  18. 18

    Attaining sinus rhythm mediates improved outcome with early rhythm control therapy of atrial fibrillation: the EAST-AFNET 4 trial.

    Eckardt L, Sehner S, Suling A, et al.

    European heart journal 2022; (43(40)):4127-4144 doi:10.1093/eurheartj/ehac471.

    PMID: 36036648
  19. 19

    Pharmacological cardioversion of atrial fibrillation: practical considerations.

    Wybraniec MT, Kampka Z, Mizia-Stec K

    Polish archives of internal medicine 2023; (133(9)) doi:10.20452/pamw.16547.

    PMID: 37622443
  20. 20

    Left atrial volume index: A predictor of atrial fibrillation recurrence following direct current cardioversion - A systematic review and meta-analysis.

    Raniga D, Goda M, Hattingh L, et al.

    International journal of cardiology. Heart & vasculature 2024; (51()):101364 doi:10.1016/j.ijcha.2024.101364.

    PMID: 38426114
  21. 21

    Cardioversion in Non-Valvular Atrial Fibrillation.

    Klein HH, Trappe HJ

    Deutsches Arzteblatt international 2015; (112(50)):856-62.

    PMID: 26763380
  22. 22

    Transesophageal Echocardiogram Before Cardioversion in Atrial Fibrillation Patients.

    Adedara VO, Sharma V, Nawaz H, et al.

    Cureus 2023; (15(5)):e39702 doi:10.7759/cureus.39702.

    PMID: 37398783
  23. 23

    Cabins, castles, and constant hearts: rhythm control therapy in patients with atrial fibrillation.

    Willems S, Meyer C, de Bono J, et al.

    European heart journal 2019; (40(46)):3793-3799c doi:10.1093/eurheartj/ehz782.

    PMID: 31755940
  24. 24

    Early Rhythm Control Therapy in Patients With Atrial Fibrillation and Heart Failure.

    Rillig A, Magnussen C, Ozga AK, et al.

    Circulation 2021; (144(11)):845-858 doi:10.1161/CIRCULATIONAHA.121.056323.

    PMID: 34328366
  25. 25

    [Update of the ESC atrial fibrillation guidelines : From the DGK commission for clinical cardiovascular medicine].

    Schnabel RB, Gunawardene MA, Perings CA, et al.

    Herzschrittmachertherapie & Elektrophysiologie 2025; (36(3)):226-232 doi:10.1007/s00399-025-01096-4.

    PMID: 40745101

This page explains rate and rhythm control options for atrial fibrillation for educational purposes and is not medical advice. Your cardiology team should choose medications, heart-rate targets, anticoagulation, or procedures for your situation.

Get notified when new evidence is published on atrial fibrillation.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.